MX2024010075A - Canales iónicos activados por ligando y métodos de uso - Google Patents
Canales iónicos activados por ligando y métodos de usoInfo
- Publication number
- MX2024010075A MX2024010075A MX2024010075A MX2024010075A MX2024010075A MX 2024010075 A MX2024010075 A MX 2024010075A MX 2024010075 A MX2024010075 A MX 2024010075A MX 2024010075 A MX2024010075 A MX 2024010075A MX 2024010075 A MX2024010075 A MX 2024010075A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- ligand
- ion channels
- gated ion
- engineered receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311735P | 2022-02-18 | 2022-02-18 | |
| US202263348560P | 2022-06-03 | 2022-06-03 | |
| PCT/US2023/062943 WO2023159247A1 (en) | 2022-02-18 | 2023-02-21 | Ligand gated ion channels and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010075A true MX2024010075A (es) | 2024-11-08 |
Family
ID=87579027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010075A MX2024010075A (es) | 2022-02-18 | 2024-08-15 | Canales iónicos activados por ligando y métodos de uso |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250163130A1 (https=) |
| EP (1) | EP4479421A4 (https=) |
| JP (1) | JP2025508427A (https=) |
| KR (1) | KR20240161957A (https=) |
| CN (1) | CN119137143A (https=) |
| AU (1) | AU2023221946A1 (https=) |
| CA (1) | CA3252386A1 (https=) |
| IL (1) | IL315059A (https=) |
| MX (1) | MX2024010075A (https=) |
| WO (1) | WO2023159247A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693172B1 (en) * | 1999-05-27 | 2004-02-17 | Pharmacia And Upjohn Company | Double mutant alpha-7 nicotinic acetylcholine receptor |
| IL304040B2 (en) * | 2016-07-07 | 2024-09-01 | Hughes Howard Med Inst | Modified ligand-gated ion channels and methods of use |
| US10538571B2 (en) * | 2017-11-27 | 2020-01-21 | Coda Biotherapeutics, Inc. | Compositions and methods for neurological diseases |
| AU2020334147A1 (en) * | 2019-08-21 | 2022-03-31 | Trames Bio, Inc. | Compositions and methods for neurological diseases |
-
2023
- 2023-02-21 KR KR1020247030756A patent/KR20240161957A/ko active Pending
- 2023-02-21 CN CN202380034556.XA patent/CN119137143A/zh active Pending
- 2023-02-21 AU AU2023221946A patent/AU2023221946A1/en active Pending
- 2023-02-21 US US18/839,624 patent/US20250163130A1/en active Pending
- 2023-02-21 WO PCT/US2023/062943 patent/WO2023159247A1/en not_active Ceased
- 2023-02-21 IL IL315059A patent/IL315059A/en unknown
- 2023-02-21 EP EP23757172.4A patent/EP4479421A4/en active Pending
- 2023-02-21 JP JP2024548618A patent/JP2025508427A/ja active Pending
- 2023-02-21 CA CA3252386A patent/CA3252386A1/en active Pending
-
2024
- 2024-08-15 MX MX2024010075A patent/MX2024010075A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4479421A1 (en) | 2024-12-25 |
| EP4479421A4 (en) | 2026-02-25 |
| WO2023159247A1 (en) | 2023-08-24 |
| KR20240161957A (ko) | 2024-11-13 |
| AU2023221946A1 (en) | 2024-09-12 |
| US20250163130A1 (en) | 2025-05-22 |
| IL315059A (en) | 2024-10-01 |
| CN119137143A (zh) | 2024-12-13 |
| JP2025508427A (ja) | 2025-03-26 |
| CA3252386A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202408862B (en) | Compositions and methods for neurological diseases | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| MX2025001810A (es) | Compuestos que participan en la union cooperativa y usos de los mismos | |
| MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
| CL2020002161A1 (es) | Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano. | |
| AU2018372763A1 (en) | Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa | |
| WO2020252397A8 (en) | Small molecule proteolysis-targeting chimeras and methods of use thereof | |
| MY203469A (en) | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy | |
| BR112018068906A2 (pt) | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo | |
| ATE554800T1 (de) | Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe | |
| AR114350A1 (es) | Terapia genética para la distrofia muscular de cinturas del tipo 2c | |
| JOP20190200A1 (ar) | تركيبات نافعة في معالجة ضمور العضل النخاعي | |
| BR112021015616A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
| ES2539790T3 (es) | Métodos y composiciones para modular c-met hiperestabilizado | |
| MX2023009714A (es) | Metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina. | |
| BR112022008821A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| EA201891913A1 (ru) | Улучшенные препараты клеток-предшественников взрослой печени | |
| WO2021048619A3 (en) | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment | |
| WO2022251167A3 (en) | Methods and materials for treating a stroke | |
| MX2023004020A (es) | Anticuerpos anti-ngf y métodos para su uso. | |
| WO2022040535A3 (en) | Compositions and methods for neurological diseases | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| MX2023013053A (es) | Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de estereocilina. | |
| MX2024010075A (es) | Canales iónicos activados por ligando y métodos de uso |